• Strategic Thinking 

    Customized Recommendations 

    Effective Execution 
    ​
    Quality

  • ​Strategic Thinking 

    Customized Recommendations 

    Effective Execution 
    ​
    Quality

  • ​Strategic Thinking 
    ​
    Customized Recommendations 

    Effective Execution 
    ​
    Quality

  • Strategic Thinking 

    Customized Recommendations 

    Effective Execution 
    ​
    Quality

  • Strategic Thinking 

    Customized Recommendations 

    Effective Execution 
    ​
    Quality

​About Us

​MRGN Advisors was established in 2015 to advise CEOs, supervisory boards and investors

​Consulting

​MRGN designs innovative solutions customized to clients' needs

​Contact Us

​E-mail: info@mrgnadvisors.com

​Welcome to MRGN Advisors

​Pierre A. MORGON

Pierre A. MORGON is CEO of MRGN Advisors, Executive Vice President, Portfolio Strategy and Supranational Affairs at CanSino Biologics and Regional Partner for Switzerland at Merieux Equity Partners.

He is Chairman of the Boards of Theradiag, Eurocine Vaccines, MYCB1, Adiposs, Kupando and Health Technologies Holding, as well as Non-Executive Director to the Boards of Vaccitech, Univercells, Amoeba and Limula.​
​
Read More

​Latest News

Scientists urged the Biden administration to launch an ‘Operation Warp Speed’ to develop inhaled COVID vaccines. China beat the U.S. to the punch​
Read the article
A Chinese COVID-19 vaccine maker explains why it hasn’t published any late-stage data yet
​Read the article
COVID-19, UN VAUDOIS AU SERVICE DU VACCIN CHINOIS​
Read more
Appointment of Pierre Morgon as Chairman of the Board of Directors of Theradiag
Read more

​Capabilities

​Health Care
​MRGN Advisors is involved in healthcare infrastructure projects in Switzerland, such as the set-up of specialized surgical centers and clinics.
​Consulting
​MRGN designs innovative solutions customized to clients’ needs, aiming at maximizing the value of product development, market access, manufacturing footprint, launch and life cycle management.
​Pharmaceuticals
​MRGN Advisors provides an exclusive competitive edge in the pharmaceutical sector by leveraging firsthand experience of the environment, anticipate trends and translate them into opportunities for our clients in the fields of Oncology, Cardiovascular, Central Nervous System, Dermatology and Allergology.
​Biologics
​MRGN Advisors capitalizes on direct operational experience in healthcare investment and operations management to deliver innovation, business development and partnering, funding and access strategies.
​Vaccines
​MRGN advisors brings decades of expertise in both multinational and start-up vaccine companies, and a worldwide network of experts spanning the entire value chain of vaccines, delivering cutting-edge solutions for research, development, manufacturing, regulatory, market access and immunization policy strategies.
​Med Tech
​MRGN Advisors capitalizes on a unique understanding of the med tech sector in Switzerland to provide insights to investors and companies in designing innovation, partnering, financing and market access strategies.
​Digital Health
​MRGN Advisors is providing insights to investors and healthcare companies looking for opportunities in the fast evolving, vibrant and sometimes confusing sector of healthcare IT.